Literature DB >> 228832

Neurologic involvement in glucagonoma syndrome: response to combination chemotherapy with 5-fluorouracil and streptozotocin.

J D Khandekar, D Oyer, H J Miller, N A Vick.   

Abstract

A 34-year-old man presented with classic glucagonoma syndrome manifested by weight loss, dermatitis, stomatitis, anemia, and mild diabetes mellitus. The diagnosis of glucagonoma was made by light and electron microscopic demonstration of a metastatic alpha cell carcinoma in a liver biopsy specimen. Plasma glucagon concentration was abnormally high. The patient also had symptoms and signs of involvement of the central nervous system. Radionuclide and CAT scans of the brain, negative CSF cytology and myelography excluded the possibility of metastases or other space-occupying lesions. Glucagon was demonstrated in the CSF. We postulate that the neurologic symptoms were due to direct or indirect effect of this hormone on the brain. Following therapy with streptozotocin and 5-fluorouracil, the patient had a subjective and objective clinical and hormonal remission of his disease including amelioration of his neurological impairment.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 228832     DOI: 10.1002/1097-0142(197912)44:6<2014::aid-cncr2820440608>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

Review 1.  A review of the therapy of paraneoplastic neurologic syndromes.

Authors:  A Das; F H Hochberg; S McNelis
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Retrobulbar neuritis as the first sign of the glucagonoma syndrome.

Authors:  E R Lambrecht; T L van der Loos; A H van der Eerden
Journal:  Int Ophthalmol       Date:  1987-10       Impact factor: 2.031

Review 3.  Response of paraneoplastic syndromes to antineoplastic therapy.

Authors:  M Markman
Journal:  West J Med       Date:  1986-05

4.  Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome.

Authors:  Stephanie A C Halvorson; Erin Gilbert; R Samuel Hopkins; Helen Liu; Charles Lopez; Michael Chu; Marie Martin; Brett Sheppard
Journal:  J Gen Intern Med       Date:  2013-05-17       Impact factor: 5.128

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.